Download presentation
Presentation is loading. Please wait.
Published byJutta Rantanen Modified over 6 years ago
1
Safeguarding future antimicrobial options: strategies to minimize resistance
R. Leclercq Clinical Microbiology and Infection Volume 7, Pages (January 2001) DOI: /j s3018.x Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions
2
Fig 1 Increased prescribing of new macrolides is proportional to increased macrolide resistance among S. pneumoniae. New macrolides include agents with longer half-lives, i.e. spiramycin, roxithromycin, clarithromycin and azithromycin; old macrolides include agents with shorter half-lives, i.e. erythromycin, dirithromycin and josamycin. Resistance is defined as erythromycin MIC ≥1 mg/L. (figure adapted from [5]) Clinical Microbiology and Infection 2001 7, 18-23DOI: ( /j s3018.x) Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions
3
Fig 2 Emergence of macrolide resistance (grey) in group A streptococci in Finland and its relationship to macrolide consumption (black). Macrolide resistance defined as erythromycin MIC ≥1 mg/L. (figure adapted from [6,7]) Clinical Microbiology and Infection 2001 7, 18-23DOI: ( /j s3018.x) Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions
4
Fig 3 Levels of resistance to non-β-lactam antimicrobials according to penicillin susceptibility among isolates of S. pneumoniae from a 1992–93 Western European and USA collaborative surveillance study [15]. Clinical Microbiology and Infection 2001 7, 18-23DOI: ( /j s3018.x) Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions
5
Fig 4 Induction of erythromycin A resistance in an inducibly resistant strain of S. pneumoniae incubated with subinhibitory concentrations of macrolides or telithromycin and subsequently challenged with 50 mg/L erythromycin A. Ery, erythromycin A; TEL, telithromycin; CC, uninduced control culture. (figure adapted from [20]) Clinical Microbiology and Infection 2001 7, 18-23DOI: ( /j s3018.x) Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.